A 56 year old man presenting with stage III melanoma was treated with ipilimumab therapy. After his second cycle of ipilimumab he developed severe abdominal cramping and non-bloody diarrhea. Colonoscopy revealed diffuse moderate inflammation (erosions, erythema, granularity, loss of vascularity) from transverse colon to the rectum (Fig. 1) . Biopsy results revealed colonic mucosa with patchy, lymphoplasmacytic infiltrate within the lamina propria, cryptitis, apoptotic bodies, and damaged surface epithelium (Fig. 2) .
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He was treated with intravenous corticosteroids followed by prednisone 60 mg daily for ipilimumab-induced colitis. His symptoms persisted; therefore a single dose of infliximab 5 mg/ kg was given. He clinically responded to infliximab and was able to be tapered off prednisone.
Ipilimumab is an anticytotoxic T-lymphocyte antigen-4 antibody, FDA approved for unresectable or metastatic melanoma. Ipilimumab-induced colitis is well recognized and can present 5-10 weeks after an infusion. Presenting symptoms include diarrhea, abdominal pain, hematochezia, ileus, and bowel perforation.
In patients in whom disease proves steroid refractory, treatment with infliximab is recommended [1] . Ipilimumab activates T cells and the production of cytokines; infliximab counters this by suppression of cytokines interleukin 1 and 6. In patients in whom symptoms resolve after infliximab, steroids
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should be tapered over 45-60 days. If patients flare during the taper, a re-taper of steroids [2] or another dose of infliximab may be required [3] .
Given the widespread use of ipilimumab and the high rates of ipilimumab-induced colitis, it is important for gastroenterologists to understand the role infliximab plays in the treatment of steroid-refractory cases.
